China Shenghuo Pharmaceutical Holdings, Inc. to Launch 12Ways(R) Advertisement on CCTV in January 2008

China Shenghuo Pharmaceutical Holdings, Inc. to Launch 12Ways(R) Advertisement on CCTV in January 2008

KUNMING, China, Dec. 6 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (AMEX:KUN), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it has won a bid to launch its new television commercial promoting China Shenghuo's 12Ways(R) Chinese Herbal Cosmetics on China Central Television ("CCTV").

This is the first time a Chinese herbal cosmetics manufacturer has won commercial airtime in CCTV's most popular time slot. Beijing Xinxin Changrong Advertising Co., Ltd. served as the agent for the bid.

Under terms of the agreement, which runs from January 1, 2008, through December 31, 2008, China Shenghuo's 12Ways Chinese Herbal Cosmetics will be featured in a 15-second segment aired 10 times per day on CCTV Channels 1, 3 and 8.

"We are excited to increase our customers' awareness of Chinese herbal cosmetics by launching the 12Ways television commercials on CCTV, which is well-recognized in China," said Mr. Gui Hua Lan, China Shenghuo's Chairman and Chief Executive Officer. "China's hosting of the 2008 Olympics will bring enormous attention to the event and the nation from all over the world. This provides us with an excellent opportunity to increase the public's awareness of 12Ways skin care, which is an essential part of the product line's success."

CCTV is the national television network of the People's Republic of China. It features 15 channels with combined daily airtime of more than 200 hours and attracts more than 1 billion viewers, covering more than 90% of China's population.

Following the Company's full-scale launch of its 12Ways series in September, China Shenghuo has opened more than 10 retail counters in pharmacies in Beijing, Shanghai, Zhejiang, Fujian and Sichuan provinces. China Shenghuo hopes to operate 100 retail counters by the end of 2008.

12Ways caters to modern women, who are typically interested in products that are both effective and safe. The name was inspired by Chinese tradition, which says the number 12 connotes harmony and good luck. China Shenghuo has set up three sales and marketing offices in Beijing, Guangzhou and Shanghai to better support sales in local regions.

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn/

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company's business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc
Ms. Gao Qionghua, CFO
Tel: +86-871-728-2608
Email: qionghua_kmsh@163.com

CCG Elite Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com

Source: China Shenghuo Pharmaceutical Holdings, Inc.

CONTACT: Ms. Gao Qionghua, CFO of China Shenghuo Pharmaceutical Holdings,
Inc., +86-871-728-2608, or qionghua_kmsh@163.com; Crocker Coulson, President
of CCG Elite Investor Relations, +1-646-213-1915 (New York), or
crocker.coulson@ccgir.com, both for China Shenghuo Pharmaceutical Holdings,
Inc.

Web site: http://www.shenghuo.com.cn/

-------
Profile: intent